Background: The CAROLINA, landmark cardiovascular outcome trial (CVOT) , has demonstrated cardiovascular safety of glimepiride against DPP-IV inhibitor linagliptin. Considering the absence of CVOT for Gliclazide, we decided to conduct a systematic review of the literature to assess the cardiovascular (CV) safety and hypoglycemia risk of gliclazide versus linagliptin in patients with T2DM.

Method: A systematic literature search of MEDLINE and Google Scholar was conducted to include all linagliptin ± metformin and gliclazide ± metformin trials from 20onwards that assessed the adverse events: hypoglycemia, myocardial infarction/ischemia, transient ischemic attack, cardiovascular death, and stroke. Two independent reviewers conducted a literature search and study selection according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Only randomized trials, considered the highest quality of evidence by the Oxford Center for Evidence-based Medicine, were included. We excluded placebo-controlled studies and studies comparing gliclazide or linagliptin with metformin.

Results: No trials compared gliclazide ± metformin with linagliptin ± metformin. Hence, it was impossible to directly compare their hypoglycemia and major adverse cardiovascular events (MACE) outcomes. Eight clinical trials were included in the narrative descriptive synthesis (gliclazide 5 and linagliptin 3) . Both drugs effectively achieved the desired glycaemic control and had low MACE and hypoglycemia risk in adults with T2DM. Studies comparing gliclazide with another DPP4 inhibitor, vildagliptin, did not report a significant difference in CV safety and/or hypoglycemia incidence.

Conclusion: Gliclazide can be used safely in patients with T2D in resource-limited settings as it has low MACE and hypoglycemia risk.


V.Mohan: None. S.Wangnoo: None. S.Das: n/a. R.Dhediya: None. K.Gaurav: Employee; Dr. Reddy’s Laboratories Ltd.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at